20 Participants Needed

Pembrolizumab + Ibrutinib for Melanoma

No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise

Trial Summary

What is the purpose of this trial?

This phase I trial studies the best dose of ibrutinib when given together with pembrolizumab in treating patients with stage III-IV melanoma that cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and ibrutinib may work better in treating patients with melanoma.

Research Team

Matthew S. Block, M.D., Ph.D. - Doctors ...

Matthew S. Block, MD, PhD

Principal Investigator

Mayo Clinic in Rochester

Eligibility Criteria

This trial is for adults with advanced melanoma (stage III-IV) that can't be surgically removed. They should have a certain level of physical fitness, adequate organ function, and no recent treatments or severe illnesses that could interfere with the study. Pregnant women and those not using contraception are excluded.

Inclusion Criteria

My melanoma cannot be surgically removed and has spread beyond its original site.
My liver function tests are within the required range.
I can take care of myself and am up and about more than half of my waking hours.
See 11 more

Exclusion Criteria

I have not had any major surgery in the last 28 days.
I have been treated with ibrutinib or other BTK inhibitors before.
I am currently breastfeeding.
See 23 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Patients receive ibrutinib orally daily and pembrolizumab intravenously as part of a dose-escalation study

28 days for cycle 1, 21 days for subsequent cycles
Cycle 1: 1 visit (in-person), Subsequent cycles: 1 visit every 21 days (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

Every 6 months for 5 years
Follow-up visits every 6 months

Treatment Details

Interventions

  • Ibrutinib
  • Pembrolizumab
Trial Overview The trial is testing the combination of two drugs: Pembrolizumab, an antibody that may boost the immune system's attack on cancer, and Ibrutinib, which might stop tumor growth by blocking specific enzymes. The goal is to find the best dose of Ibrutinib to use alongside Pembrolizumab.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Treatment (ibrutinib, pembrolizumab)Experimental Treatment3 Interventions
Patients receive ibrutinib PO daily on days 1-28 of cycle 1 and days 1-21 of cycle 2 and subsequent cycles. Patients also receive pembrolizumab IV over 30 minutes on day 8 of cycle 1 and day 1 of cycle 2 and subsequent cycles. Cycle 1 continues for 28 days and subsequent cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Ibrutinib is already approved in European Union, United States, Canada, Japan for the following indications:

🇪🇺
Approved in European Union as Imbruvica for:
  • Chronic lymphocytic leukemia
  • Mantle cell lymphoma
  • Waldenström's macroglobulinemia
  • Marginal zone lymphoma
  • Graft-versus-host disease
🇺🇸
Approved in United States as Imbruvica for:
  • Chronic lymphocytic leukemia/small lymphocytic lymphoma
  • Mantle cell lymphoma
  • Waldenström's macroglobulinemia
  • Marginal zone lymphoma
  • Graft-versus-host disease
🇨🇦
Approved in Canada as Imbruvica for:
  • Chronic lymphocytic leukemia
  • Mantle cell lymphoma
  • Waldenström's macroglobulinemia
  • Marginal zone lymphoma
🇯🇵
Approved in Japan as Imbruvica for:
  • Chronic lymphocytic leukemia
  • Mantle cell lymphoma
  • Waldenström's macroglobulinemia

Find a Clinic Near You

Who Is Running the Clinical Trial?

Mayo Clinic

Lead Sponsor

Trials
3,427
Recruited
3,221,000+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security